Luo DS, Li YQ, Deng ZQ, Liu GH. Progress and prospect of stem cell therapy for diabetic erectile dysfunction. World J Diabetes 2021; 12(12): 2000-2010 [PMID: 35047115 DOI: 10.4239/wjd.v12.i12.2000]
Corresponding Author of This Article
Guihua Liu, MD, PhD, Associate Chief Physician, Associate Research Scientist, Reproductive Centre, Sun Yat-Sen University, The Sixth Affiliated Hospital, No. 26 Yuancuner Rd., Tianhe District, Guangzhou 510000, Guangdong Province, China. liuguihua@mail.sysu.edu.cn
Research Domain of This Article
Andrology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Dec 15, 2021; 12(12): 2000-2010 Published online Dec 15, 2021. doi: 10.4239/wjd.v12.i12.2000
Progress and prospect of stem cell therapy for diabetic erectile dysfunction
Dao-Sheng Luo, Yan-Qing Li, Zhi-Quan Deng, Gui-Hua Liu
Dao-Sheng Luo, Zhi-Quan Deng, Department of Urology, Dongguan People’s Hospital, Dongguan 523000, Guangdong Province, China
Yan-Qing Li, Gui-Hua Liu, Reproductive Centre, Sun Yat-Sen University, The Sixth Affiliated Hospital, Guangzhou 510000, Guangdong Province, China
Author contributions: Liu GH and Luo DS designed the research study; Luo DS and Li YQ performed the literature retrieval and analysis; Li YQ and Deng ZQ wrote the manuscript; All authors have read and approved the final manuscript.
Supported bythe National Natural Science Foundation of China, No. 81971759.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest associated with this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guihua Liu, MD, PhD, Associate Chief Physician, Associate Research Scientist, Reproductive Centre, Sun Yat-Sen University, The Sixth Affiliated Hospital, No. 26 Yuancuner Rd., Tianhe District, Guangzhou 510000, Guangdong Province, China. liuguihua@mail.sysu.edu.cn
Received: February 6, 2021 Peer-review started: February 7, 2021 First decision: March 8, 2021 Revised: March 18, 2021 Accepted: October 31, 2021 Article in press: November 3, 2021 Published online: December 15, 2021 Processing time: 313 Days and 6 Hours
Abstract
Diabetic erectile dysfunction (DED) is a common complication of diabetes mellitus, significantly impairing the quality of life of patients. The conventional clinical treatment still has limitations. Stem cells (SCs), as a type of cells with multidirectional or directional differentiation capability and sustainable self-renewal potential, are widely used in regenerative medicine and tissue engineering. With the continuous update of regenerative medicine theory and the success of animal experiments, SCs as a treatment for male erectile dysfunction, especially DED, have attracted widespread attention because of curable possibility. This review focus on the current progress in the clinical application of SC treatment for DED. Moreover, we summarize the development prospects of SCs in the field of DMED therapy.
Core Tip: Diabetic erectile dysfunction (DED) is a common complication of diabetes. Conventional clinical treatments like phosphodiesterase-5 inhibitors, intracavernosal vasoactive drug injection, negative pressure suction device, and low-intensity shock wave therapy are the conventional methods of clinical treatment. However, none of the above therapies has the potential of curing. Stem cell therapy is currently the only possible cure for DED and can avoid the potential complications of conventional therapies. Here we discuss the current role and progress of stem cells in the treatment of DED.
